Effects of Recombinant Erythropoietin Therapy on Circulating Endothelial Markers in Hemodialysis Patients

Effects of a 4-week course of recombinant human erythropoietin (rHuEpo) therapy on four circulating endothelium-derived cardiovascular risk markers were studied in 20 patients receiving maintenance hemodialysis in relation to surrogates of chronic inflammation, liver function, and arterial blood pre...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and applied thrombosis/hemostasis 2002-01, Vol.8 (1), p.77-84
Main Authors: Borawski, Jacek, Mysiwiec, Michal
Format: Article
Language:English
Subjects:
Adult
Aged
Anemia - drug therapy
Anemia - etiology
Antibodies, Viral - blood
Antigens, Viral - blood
Biomarkers - blood
Blood pressure
Blood Proteins - analysis
Cholesterol - blood
Endothelium
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Erythropoietin - pharmacology
Erythropoietin - therapeutic use
Female
Health risk assessment
Hemodialysis
Hemodynamics - drug effects
Hemoglobins - analysis
Hepacivirus - immunology
Hepatitis B virus - immunology
Humans
Liver Function Tests
Male
Middle Aged
Phosphorus - blood
Recombinant Proteins
Renal Dialysis - adverse effects
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Effects of a 4-week course of recombinant human erythropoietin (rHuEpo) therapy on four circulating endothelium-derived cardiovascular risk markers were studied in 20 patients receiving maintenance hemodialysis in relation to surrogates of chronic inflammation, liver function, and arterial blood pressure. Soluble intercellular adhesion molecule-1 (sICAM-1), antigens of plasminogen activator inhibitor-i (PAI-i:Ag) and von Willebrand factor (vWF:Ag), and soluble thrombomodulin (sTM) were determined by immunoenzymatic assays. C-reactive protein; (xi acid-glycoprotein; ax-antitrypsin; immunoglobulin M, A, and G; interleukin-6; lipoprotein(a); fibrinogen; total protein; albumin; total cholesterol; hepatitis B and C markers; liver enzymes; prothrombin time; and phosphorus were measured by routine methods. The rHuEpo treatment resulted in a 25% increase in sICAM-1 (Wilcoxon's p = 0.001), a 50% increase in PAI-i:Ag (p = 0.004), a 15% increase in sTM (p = 0.002), and did not change vWF:Ag levels. The increase in sICAM-1 concentration directly correlated with that of PAI-i:Ag (Spearman's rho = 0.483, p = 0.031). The rHuEpo-induced increases in hemoglobin, platelets, and pre-dialysis diastolic blood pressure levels did not correlate with the increments in the endothelial markers studied. In conclusion, short-term rHuEpo therapy activates vascular endothelium in patients receiving maintenance hemodialysis. This specific effect may influence cardiovascular risk.
ISSN:1076-0296
1938-2723
DOI:10.1177/107602960200800111